{"nctId":"NCT01659853","briefTitle":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","startDateStruct":{"date":"2012-09"},"conditions":["Erythema","Rosacea"],"count":70,"armGroups":[{"label":"Overall Study","type":"EXPERIMENTAL","interventionNames":["Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle","Drug: azelaic acid gel 15%"]}],"interventions":[{"name":"CD07805/47 gel 0.5%/CD07805/47 Vehicle","otherNames":["brimonidine tartrate gel 0.5%","brimonidine tartrate gel vehicle"]},{"name":"azelaic acid gel 15%","otherNames":["Finacea® gel 15%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is male or female aged 18 years or older.\n2. Subject has a clinical diagnosis of facial rosacea.\n3. Subject has a clinician's assessment score of moderate to severe erythema prior to enrollment.\n4. Subject has a self assessment score of moderate to severe redness prior to enrollment.\n5. Subjects with none to mild facial inflammatory lesions of rosacea prior to enrollment.\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant, nursing or planning a pregnancy during the study.\n2. Subjects with a condition or who are in a situation, which in the Investigator's opinion may put a subject at risk, may confound study results, or may interfere with a subject's participation in the study.\n3. Subjects with conditions causing facial erythema which would confound the assessment of treatment.\n4. Subjects who are taking or have recently taken medications known to have interactions with α2-adrenergic agonists.\n5. Subjects with known allergies or sensitivities to one of the components of the investigational products.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Success","description":"Composite Success, defined as a 2-grade improvement at 6 hours on both the clinician's and subject's erythema assessments at the end of each treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Onset of Action","description":"Onset of action, defined as an improvement on both the clinician's and subject's erythema assessments at 30 minutes post baseline application","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Erythema","Pruritus","Medication residue","Skin burning sensation","Pain of skin"]}}}